Related Experiment Videos
[Multidisciplinary treatment for liver metastasis using cytokines]
1First Department of Surgery, Kinki University School of Medicine, Osaka-sayama, Japan.
Nihon Geka Gakkai Zasshi
|June 8, 2001
Summary
Adjuvant immunotherapy with interleukin-2 (IL-2) and chemotherapy after liver resection significantly improved survival for colorectal cancer patients with liver metastases. This approach helped prevent cancer recurrence in the liver.
Area of Science:
- Immunology
- Oncology
- Hepatology
Context:
- The liver possesses immune cells like Kupffer cells and T cells, crucial for combating liver metastasis.
- Colorectal cancer frequently metastasizes to the liver, necessitating effective treatment strategies.
Purpose:
- To evaluate the efficacy of adjuvant immunochemotherapy combined with liver resection in preventing liver recurrence in colorectal cancer patients with liver metastases.
Summary:
- A pilot study involved 20 patients with liver metastases from colorectal cancer undergoing liver resection followed by adjuvant immunochemotherapy.
- The regimen included hepatic arterial infusion of interleukin-2 (IL-2), 5-fluorouracil, and mitomycin C for 6 months.
- 14 patients survived with a median postoperative survival of 69.7 months, and the 5-year overall survival rate was 78%.
Impact:
- IL-2-based immunochemotherapy combined with liver resection shows promise in preventing liver recurrence in colorectal cancer.
- No recurrence in the residual liver was observed in patients receiving the adjuvant therapy.
- Results suggest the utility of this approach, warranting a multicenter, randomized trial.